ESTRO 2024 - Abstract Book

S2076

Clinical - Sarcoma, skin cancer, melanoma

ESTRO 2024

Standard fractionation achieved meaningful vision preservation five years after SRT for CM in high-risk locations for vision loss. Dose to the ON did not predict for BCVA. 60Gy in 30 fractions achieved acceptable 2yFFLP and 5yMFS. This dose-fractionation regimen is a paradigm shift in CM and warrants further investigation.

Keywords: choroidal melanoma, fractionation, visual acuity

References:

Chang MY and McCannel TA. Local treatment failure after globe-sparing therapy for choroidal melanoma. Br J Ophthalmol.2013;97:804-811.

Dunavoelgyi R, Zehetmayer G, Schmidt-Erfurth U, Pötter R et al. Dose response of critical structures in the posterior eye segment to hypo fractionated stereotactic photon radiotherapy of choroidal melanoma. Radiotherapy Oncol 2013;108:348-353

Antony R, Herschtal A, Todd S, Phillips C, Haworth A, A pilot study on geometrical uncertainties for intraocular cancers in radiotherapy. Australasian Physical & Engineering Sciences in Medicine 2017; 40: 433-439

109

Poster Discussion

Quality of life in patients with skull base chordoma and chondrosarcoma after proton therapy

Katarina Bryjova 1,2 , Paul-Henry Mackeprang 2 , Ulrike Lisa Kliebsch 1 , Damien Charles Weber 1,2,3

1 Paul Scherrer Institute, Center for Proton Therapy, 5232 Villigen, Switzerland. 2 Inselspital, Bern University Hospital, Department of Radiation Oncology, 3012 Bern, Switzerland. 3 University Hospital of Zürich, Department of Radiation Oncology, 8091 Zürich, Switzerland

Purpose/Objective:

Proton therapy (PT) is well established for patients with skull base chordoma and chondrosarcoma (ChoSa), as it has been proven to have a high efficacy while maintaining a favorable side-effect profile. Given the substantial survival expectancy of these patients, their posttreatment well-being is of a paramount importance. The objective of this study is to assess the health-related quality of life (HRQoL) of these patients.

Material/Methods:

The total of 77 adult patients with a skull base chordoma or ChoSa completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30, Version 3.0) and the Brain Neoplasm 20 Module Questionnaire (BN20) prior to the proton therapy, directly at the end of it and annually